Inception Sciences is a drug discovery engine co-founded with Versant Ventures in 2011, with operating sites in the US (San Diego) and Canada (Vancouver and Montreal). Inception Sciences creates new companies in partnership with pioneering academic researchers and major biopharmaceutical companies, which provide funding and a path to liquidity though pre-negotiated acquisitions.
Drug discovery operations are built around an experienced team of researchers. Previous accomplishments of Inception team members led to multiple marketed and clinical-stage drugs in diverse disease areas including arthritis, neurology, oncology, fibrosis, osteoporosis, arthritis and respiratory disorders. Prior to Inception, team members comprised Amira Pharmaceuticals, a company successfully acquired by Bristol Myers Squibb in 2011.
Inception’s business model includes “Build-to-Buy” partnerships, where world-class academic researchers are matched with pharmaceutical partners to form new drug discovery programs for the Inception team to execute upon. New start-up companies are spun-out for translation of these programs into novel therapies, incorporating an exclusive option for a pharmaceutical partner to acquire a spun-out company downstream at pre-set terms. Inception has now formed multiple companies around discovery programs subject to Build-to-Buy agreements, including Inception 1 (partnered with Shire), Inception 3 (partnered with Roche), Inception 4 (partnered with Bayer) and Inception 5 (partnered with Roche).